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Amylin e Its role in the homeostatic and hedonic
control of eating and recent developments of
amylin analogs to treat obesity
Christina Neuner Boyle, Thomas Alexander Lutz*, Christelle Le Foll
ABSTRACT
Background: Amylin is a pancreatic b-cell hormone that produces effects in several different organ systems. One of its best-characterized
effects is the reduction in eating and body weight seen in preclinical and clinical studies. Amylin activates speciﬁc receptors, a portion of
which it shares with calcitonin gene-related peptide (CGRP). Amylin’s role in the control of energy metabolism relates to its satiating effect, but
recent data indicate that amylin may also affect hedonic aspects in the control of eating, including a reduction of the rewarding value of food.
Recently, several amylin-based peptides have been characterized. Pramlintide (Symlin) is currently the only one being used clinically to treat
type 1 and type 2 diabetes. However other amylin analogs with improved pharmacokinetic properties are being considered as anti-obesity
treatment strategies. Several other studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in
combination with other agents.
Scope of review: This review will brieﬂy summarize amylin physiology and pharmacology and then focus on amylin’s role in food reward and the
effects of amylin analogs in pre-clinical testing for anti-obesity drugs.
Conclusion: We propose here that the effects of amylin may be homeostatic and hedonic in nature.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. AMYLIN IN THE CONTROL OF ENERGY METABOLISM
The pancreatic hormone amylin is co-synthesized and co-released
with insulin from pancreatic beta-cells [1e3]. It has long been
thought that pancreas-derived amylin is the only relevant source of
amylin to control metabolism. However, recent evidence has shown
that amylin is also expressed in the central nervous system, in
particular in parts involved in metabolic control, such as the lateral
hypothalamus (LH) [4]. Globally, amylin controls nutrient ﬂuxes by
reducing energy intake, modulating nutrient utilization and increasing
energy expenditure. The best-investigated function of amylin is its role
as satiation signal. Indeed, chronic administration of amylin reduces
total energy intake, which eventually results in the reduction of body
weight [5,6]. These ﬁndings were the basis for the development of
amylin analogs that may represent a new approach for the treatment of
overweight in obese individuals [7,8].
The caudal hindbrain area postrema (AP) and nucleus of the solitary
tract (NTS) are critically involved in mediating the effects of amylin on
eating [9]. However, recent data indicate that other areas of the brain,
including the hypothalamic arcuate (ARC) or ventromedial (VMN) nu-
cleus [10,11], ventral tegmental area (VTA) [12,13], and lateral dorsal
tegmental nucleus (LDTg) [14], may be directly or indirectly targeted by
amylin to inﬂuence hedonic aspects of eating such as reward-guided
behaviors that may contribute to the food selection [15,16]. This review
will brieﬂy summarize amylin physiology and pharmacology and then
focus on the amylin’s role in food reward and the effects of amylin
analogs in pre-clinical testing for anti-obesity drugs. We have also
included some previously unpublished, original data, because we
believe that these data are important to introduce and emphasize
certain aspects covered in this review article. These points are
important because they have not been covered in other, recently
published review articles on amylin. Experimental details in respect to
these unpublished data are provided in the Supplementary part of this
review.
2. AMYLIN RECEPTOR STRUCTURE AND FUNCTION
The amylin receptor consists of a heterodimer of the calcitonin receptor
(CTR) core protein combined with one or several receptor activity
modifying proteins (RAMPs) to yield speciﬁc amylin receptors [8,17e
19]. Two splice variants of the CTR and three RAMPs are known,
resulting in at least 6 different subtypes of amylin receptors. Recent
data from the caudal hindbrain indicate that individual neurons may in
fact express more than a single RAMP, theoretically increasing the
number of possible amylin receptor subtypes per cell [20]. Amylin
receptor components are widely distributed throughout the central
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nervous system, and a high density of both the CTR and RAMPs is
found in the AP of the caudal hindbrain, other circumventricular organs
(e.g., the subfornical organ), the hypothalamus (ARC, VMN) and other
brain areas (VTA, LDTg, nucleus accumbens [NAc]) [21e24]. So far,
the co-expression of the CTR and RAMPs in single neurons of native
tissue has only been shown in the AP of the caudal hindbrain [20], but
our work has also shown that non-neuronal cells, in particular
microglia, also seem to mediate amylin’s effects [10,25,26].
Study of amylin receptor function is complicated by the fact that an-
tagonists that speciﬁcally block certain subtypes of amylin receptors
are not available [8,27], and prototypical amylin receptors (in particular
the amylin-1 receptor resulting from the combination of CTR and
RAMP1) also seem to mediate the effects of the related peptide
calcitonin gene-related peptide (CGRP) [27,28]. Hence, we currently
have no clear picture of the role of speciﬁc amylin receptor subtypes
for certain amylin functions, or of the importance of the expression of
more than one RAMP in single cells.
Upon amylin receptor activation, various intracellular signaling systems
are activated. Speciﬁcally, amylin increases the expression of cyclic
GMP (cGMP) in activated AP neurons [29] and leads to a phosphory-
lation of ERK [30]. In both cases, there is evidence for a functional
relevance of these systems in amylin’s effect to reduce eating. On the
other hand, transfected cell system studies show that amylin signaling
also involves cAMP, intracellular Ca2þ, and beta-arrestin [17,22]. But
none of these has been linked to speciﬁc amylin actions as yet.
3. SITES OF AMYLIN ACTION
3.1. Amylin activation of the brainstem and neuroaxis
The AP is critically implicated in mediating amylin’s satiating effect.
Local AP administration of amylin decreases eating, while local AP
amylin antagonist injection increases it, and blocks the eating inhibi-
tory effect of peripheral amylin [31]. Further, surgical lesion [32] or a
speciﬁc deletion of noradrenergic AP neurons (see also below; [33])
block the effect of peripheral amylin on eating. In addition, a large array
of electrophysiological and imaging experiments provide conﬁrmatory
evidence for an important and most likely direct effect of circulating
amylin on AP neurons (reviewed in [9,34]).
The amylin-induced activation of AP neurons occurred to a large extent
in neurons expressing the noradrenalin synthetizing enzyme,
dopamine-beta-hydroxylase (DBH), and presumably the subsequent
enhanced release of noradrenaline, possibly in the NTS or the lateral
parabrachial nucleus (LPB) [33]. These AP neurons are necessary for
peripheral amylin to reduce eating, because even a partial chemical
lesion of these neurons is sufﬁcient to abolish the eating inhibitory
effect of peripheral amylin; this type of lesion had no effect on baseline
food intake [33] and therefore circumvents the problem of a surgical
destruction of the entire AP, which itself has a negative inﬂuence on
eating and body weight gain [16,32].
The activation of AP neurons is the ﬁrst step in the subsequent acti-
vation of a neural pathway that projects rostrally to the forebrain and
includes the NTS, LPB, and possibly the central amygdala (CeA). Le-
sions of the respective brain areas (AP, NTS, LPB) abolish amylin’s
effect on eating and the expression of the neuronal activation marker
c-Fos, indicating that activation was absent in brain areas rostral to the
lesion, e.g. in the NTS, LPB, and CeA in AP-lesioned rats, or in the CeA
in LPB-lesioned rats [9,35,36]. Indeed using anterograde and retro-
grade tracing, the AP was shown to project to the NTS, LPB, CeA, and
the bed nucleus of the stria terminalis [37].
Furthermore, a recent study suggested that glutamatergic neuro-
transmission in the AP seems to play a role in mediating amylin effects
on eating, and that the amylin receptors appear to be located mainly on
presynaptic glutamatergic terminals synapsing with AP neurons [38];
interestingly, our own studies also showed a close apposition of
amylin-activated neurons that expressed DBH with VGLUT2-positive
boutons [39]. How these effects may be linked mechanistically, and
whether this mechanism is physiologically relevant, is currently
unknown.
3.2. Amylin action in other brain areas
As mentioned, amylin binding sites have widespread distribution
throughout the brain [21]. Similarly, the expression of all critical amylin
receptor components has also been described in many brain areas
[23,24], and amylin itself may also be expressed selectively in the
lateral hypothalamic area [4], although the contribution of the latter to
the physiological control of eating remains largely unknown. Recent
experiments focused on how amylin receptors in other brain areas
outside the AP mediate the physiological actions of peripheral amylin.
Among the most prominent of these is the VTA, where components
forming the active amylin receptor complex are expressed and where
the peripheral administration of the amylin receptor agonist salmon
calcitonin (sCT) reduces eating by activating amylin receptors.
Importantly, this effect was blocked by the VTA administration of the
amylin antagonist AC187 [12,13].
The LDTg has been implicated in processing signals related to the
homeostatic but also the hedonic control of eating. It expresses all
components of the amylin receptor, and administration of amylin or
sCT into the LDTg reduces eating primarily by reducing meal size,
similar to amylin’s satiating action in the AP [14,40]. Furthermore,
administration of the amylin receptor antagonist AC187 into the LDTg
reduces the inhibitory effect of peripheral sCT on eating, and depletion
of the CTR component leads to increased body weight gain suggesting
a physiological relevance of these ﬁndings [14].
The relationship between the effects mediated by intra-VTA or intra-
LDTg administration of sCT and the previously described AP-
mediated effects of amylin and its receptor agonists is unclear at
present. Indeed, it is not clear if amylin and its agonists activate several
brain areas in parallel. With the exception of the circumventricular
organs, including the AP, it is also unclear how much peripheral amylin
actually reaches these respective receptor populations as a function of
transport across the blood brain barrier [41e43]. It needs to be tested
whether similarly to leptin [44], amylin crosses the tanycyte layer
around the 3rd ventricle in particular to reach hypothalamic areas.
Finally, available data do not distinguish between a direct activation of
the pertinent receptors by peripheral amylin or sCT or activation
elsewhere (possibly in the AP) and mediation of this effect via pro-
jection to the VTA or LDTg, both of which may use CGRP as neuro-
transmitter interacting with the amylin-1 receptor [27].
4. AMYLIN ACTION ON FOOD REWARD
Conceptually, controls of eating have often been classiﬁed as ho-
meostatic, acting via the caudal hindbrain, including the AP, NTS and
LPB, and the hypothalamus, and hedonic, acting via reward pathways
in the brain (e.g. [45e48]). However, this distinction is probably over-
simplistic since hedonic controls of eating through reward pathways
interact with homeostatic control pathways and often can rely on the
same signaling molecules. For example, gastrointestinal hormones
such as glucagon-like peptide-1 (GLP-1) not only act as homeostatic
signals that are involved in the control of meal size or body weight but
also inﬂuence rewardebased aspects of ingestive behavior [49,50].
Food reward is often divided into two components: “liking” and
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“wanting.” In particular, wanting seems to be modulated by the
mesolimbic dopamine system that includes neurons in the VTA, which
release dopamine from axon terminals in the NAc of the ventral
striatum [46,51]. Recent data indicate that amylin may be one of the
signals inﬂuencing the rewarding properties of food, and that the
mesolimbic reward pathway may be involved in these effects.
4.1. Amylin’s effect on food choices
Direct activation of amylin receptors using sCT in the VTA has been
shown to reduce not only the intake of chow, which has low palat-
ability, but also the intake of a palatable sucrose solution in rats [13].
Similar to the effect of peripheral amylin, these effects appear to be
mainly due to a reduction in meal size. Further, administration of
amylin agonists into the VTA also reduces sucrose self-administration
on a progressive ratio schedule [52]. These studies were recently
extended by showing that sCT administered into the VTA greatly
reduced the intake of fat in fat-preferring rats [13,52]. Sucrose-
preferring rats did reduce sucrose intake after sCT, but the selec-
tivity was more variable than in fat-preferring rats. Interestingly,
administration of amylin or sCT into the LDTg also reduced motivated
behaviors such as lever pressing for sucrose solution in rats, sug-
gesting that not only the consummatory phase, but also the appetitive
phase of eating is affected [14].
4.2. Amylin’s effect on highly palatable diet intake
Our own studies indicated that the effectiveness of amylin to reduce
energy intake may actually depend on the palatability of the diet offered
to animals, but there is also an important inﬂuence of the diet that is
context speciﬁc [53e55]. In recent unpublished experiments (see
Figure 1), we used rats that were exposed for different periods of time
to Ensure, a highly palatable, liquid high-fat, and high-carbohydrate
diet. Please see Supplementary part of this review for experimental
details.
Rats that were adapted to chocolate-ﬂavored Ensure in addition to
standard rat chow ingested approximately 90% of energy as Ensure
and only 10% in the form of chow. Animals that were exposed to either
chocolate Ensure or chow for 3 weeks both decreased eating in an
acute feeding test when amylin was injected into the 3rd cerebral
ventricle (i3vt; Figure 1A). Hence, long-term access to Ensure did not
reduce the sensitivity of obese rats to central amylin. Interestingly, the
outcome was very different when rats were tested after only 3 days of
exposure to chocolate Ensure. Presumably due to very strong drive to
eat early after exposure to a novel, highly palatable diet, rats appeared
to be insensitive to centrally or peripherally injected amylin (Figure 1B,
C). In contrast, amylin reduced acute intake of a high fat diet, which
was provided for 3 days and had a similar nutrient composition to
Ensure (Figure 1D). The “insensitivity” to amylin after Ensure
appeared to be linked to the presence of the chocolate ﬂavor in the
diet, which produced a very strong drive to eat, because rats with brief
exposure to unﬂavored Ensure reduced eating after amylin, similar to
amylin’s effect on intake of high fat diet-exposed rats (data not
shown).
Thus, amylin insensitivity early after exposure to the highly palatable
chocolate Ensure seemed to be more dependent on the palatable
ﬂavor and duration of exposure rather than diet composition. These
data also suggest that speciﬁc taste preference, rather than diet
Figure 1: (A) Cumulative energy intake after saline or amylin (5 pmol; i3vt injection at dark onset in undeprived rats) in rats maintained for three weeks on Ensure cacao plus
chow or on chow only; n ¼ 18e19/group. Cumulative energy intake after saline or amylin (5 pmol; i3vt injection at dark onset in undeprived rats (B, n ¼ 10/group) or 5 mg/kg s.c.
injection at dark onset after 3 h-food deprivation (C, n ¼ 32/group), respectively) in rats maintained for three days on Ensure cacao only or on chow only; (D) Cumulative energy
intake after saline or amylin (5 pmol; i3vt injection at dark onset in undeprived rats) in rats maintained for three days on Ensure cacao, a pelleted high-fat diet, or chow only;
n ¼ 6e10/group. Values are mean  SEM, symbols denote signiﬁcant differences between saline- and amylin-treated groups within the respective diet groups; *p < 0.05,
**p < 0.01, ***p < 0.001.
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composition, appeared to play the major role, indicating that homeo-
static signals may fail to inﬂuence eating when the rewarding effect is
too strong. Finally, the data showed that the “insensitivity” towards
amylin waned once the animals had had been exposed to the highly
palatable diet for an extended period.
4.3. Mechanism of amylin’s action on food reward
A possible direct implication of the mesolimbic reward system in
amylin action, and in particular of the VTA and the NAc, was indicated
by studies showing that infusion of sCT into the VTA reduced the
release of dopamine in the NAc and that dopamine receptor activation
in the NAc overcame the inhibitory effect of sCT on eating [15]. Along
these same lines, we recently reported that peripheral sCT was also
able to reduce the VTA-stimulated release of dopamine in the NAc of
rats. Interestingly, amylin itself had no such effect, suggesting that this
difference might relate more to the duration of amylin receptor acti-
vation by amylin, which is short lasting, versus sCT, which is long
lasting, than a true difference in pharmacodynamics [16].
Most importantly, like the meal-terminating properties of amylin, the
effect of peripheral sCT to reduce evoked dopamine release was ab-
sent in rats with AP or LPB lesions [16]. This suggests that, as opposed
to what had been suggested before [13,15], the effect of sCT on
reducing dopamine release in the NAc may be mediated in the reward
system through the AP and LPB, rather than by direct action on VTA
amylin receptors. Our data can be reconciled with the previously
published work by assuming that peripheral sCT (and presumably also
amylin, at least when given chronically) activates a caudal hindbrain
network including CGRP-positive projections to the VTA, where CGRP
acting on the amylin-1 receptor may reduce the activity of dopami-
nergic neurons projecting to the NAc. This model opens up the pos-
sibility that the AP and LPB are also important in mediating hedonic and
motivational processes and that homeostatic signals also interact
directly with the hedonic system and the perception of food reward.
Hence, similar to GLP-1, amylin would be another example of a
negative feedback signal acting in the hindbrain that also plays a role in
the mediation of food reward [49,50,56,57].
These studies raise a number of questions. For example, is the
sensitivity of this system and its responsiveness to amylin due to
differences in the circumstances of varying feeding situations? Does
the effect of chronic exposure to highly palatable diets differ from the
effect of short-term exposure, and if so, which is the critical compo-
nent? Is amylin “insensitivity” linked to changes in the dopaminergic
reward pathway between the VTA and NAc?
5. CLINICAL USE OF AMYLIN AND AMYLIN ANALOGS
Experience with pramlintide (Symlin) and other clinical studies in
obesity have shown that amylin agonists could also be useful for
weight loss, especially in combination with other agents [58e62]. One
of the most promising and clinically relevant combinations seems to be
amylin plus leptin [63e65]. Amylin can improve leptin sensitivity and
overcome leptin resistance in obese individuals [62]. In the following
paragraphs, the development and effects of new agonists will be
summarized, because, even though pramlintide is a useful amylin
mimetic, other amylin agonists with improved potency and pharma-
cokinetics may provide optimized therapeutics for the treatment of
obesity. Based on the ﬁndings discussed above that amylin seems to
affect homeostatic and hedonic controls of eating and that a distur-
bance of both aspects of eating is responsible for the increase in
obesity rates, amylin-based pharmacotherapy may be a particularly
promising approach for future treatment options.
Since next to its satiating action, amylin has an effect on the reward
system [15,16] and since alterations in the function of the reward
processing brain areas have been linked to mood disorders [66], it is
important to examine if amylin analogs do not induce anxiety- and
depression-like behaviors. Currently, there is no indication that this
might be the case. For example, it has been shown that rats treated
with sCT did not display an increase in anxiety type behaviors when
tested during an open ﬁeld and social interaction test [52]. Further,
chronic amylin improved the recovery from social stress in a visible
burrow system in rats [67], and long term administration of pramlintide
did not induce signs of anxiety or depression in people [62]. Some
studies indicate that amylin has anxiolytic and anti-depression like
properties (see Ref. [68] for review).
5.1. Next generation drugs for the amylin system
5.1.1. Davalintide
Davalintide is an amylinomimetic with increased potency, efﬁcacy, and
duration of action. It binds similarly to rat amylin to amylin receptors
but has greater afﬁnity than amylin at the human CGRP receptor or the
rat calcitonin receptor, at least under in vitro conditions [69]. In gen-
eral, davalintide exhibits a greatly enhanced duration of action and is
more potent than amylin in reducing food intake and body weight in
rats. Thus, davalintide shares similarities with sCT. Apart from dif-
ferences in pharmacokinetics, davalintide’s mode of action seems to
be more similar to that of amylin, because both preferentially reduced
intake of a palatable high fat diet, and the effect of both peptides on
eating appears to depend on an intact AP [69].
5.1.2. PEGylated or glycosylated amylin
Given the short half-life of the native amylin peptide (13 min), one
strategy to improve the effectiveness of amylin mimetics is to modify
the peptide chain by coupling it to molecular scaffolds such as poly-
ethylene glycol (PEG) or by glycosylation. Compared to native amylin,
PEGylated amylin has a prolonged glucose-lowering effect, but no in-
depth data are available for the effect of these compounds on eating
and body weight regulation. Further, glycosylation of the amylin analog
pramlintide also provides increased half-life compared to the native
peptide (10e15 vs. 45 min) [70e73].
5.1.3. Dual amylin and calcitonin receptor agonist (DACRA)
As discussed before, sCT is an amylin mimetic that differs from native
amylin by a prolonged activation of the amylin receptor, which leads to
enhanced and prolonged in vivo effects. Further, sCT activates not only
amylin receptors but also the classical calcitonin receptor. Based on
these ﬁndings, several dual amylin- and calcitonin receptor agonists
(DACRA) have been designed and tested for their anti-obesity and anti-
diabetes effects.
The best investigated compounds with published structures are KBP-
042, KBP-088, and KBP-089 [74e79]. KBP-042 exhibited stronger
binding afﬁnity and receptor activation at amylin and calcitonin re-
ceptors and also produced a stronger eating-inhibitory effect than sCT.
Further, KBP-042 reduced body weight more than in pair-fed controls,
indicating a potential effect on energy expenditure, effects which had
also been reported for amylin and sCT [6]. Interestingly, despite its
peptide structure, KBP-042 was also active when given orally, albeit at
much higher doses [74,77e79].
In a direct comparison between KBP-088 and davalintide, KBP-088
produced stronger effects on eating and body weight than davalin-
tide, which may be associated with the extended receptor activation
under in vitro conditions [75]. Finally, KBP-089 was shown to reduce
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eating and body weight and signiﬁcantly reduced total energy intake by
reducing the intake of energy rich diets and a relative shift towards the
intake of low energy diets in chronically treated rats [76,80].
5.1.4. Oral amylin agonists
Several studies have tested the usefulness of the oral administration of
amylin agonists. Some studies used the carrier Intravail which is a
transmucosal absorption enhancement agent. Pramlintide has been
formulated in Intravail, and the effects on energy balance and glycemic
control corresponded to the known effects of injected pramlintide [81].
Further studies showed that orally administered sCT which was
formulated in N-(5-chlorosalicyloyl)-8-aminocaprylicacid (5CNAC-sCT)
also had reduced weight and improved glucose tolerance [82e84].
5.2. Integrated circuits for the release of amylin agonists
In recent years, various approaches led to the development of engi-
neered mammalian cell systems that allow an “automated” release of
bioactive peptides to treat metabolic diseases. The underlying idea of
such systems is that synthetic gene networks are designed in a way
that allow the systems to respond to certain physiological stimuli in a
well-balanced manner to produce an appropriate amount of bioactive
molecules in a speciﬁc metabolic situation [85e88]. Next to glucose-
sensing cell systems that release insulin and that may be used for the
treatment of diabetes mellitus, a novel method has been described
recently to deliver the amylin analog pramlintide in a diet-speciﬁc
manner in mice. The engineered closed-loop synthetic gene circuit
is able to monitor blood free fatty acid levels (FFA) and to produce
pramlintide in response to elevated fatty acids. Interestingly, intra-
peritoneal implantation of the engineered cell circuits in mice led to a
reduced food intake and body weight, and it also decreased blood FFA
levels compared to respective controls [89].
Please see Supplementary part of this review for experimental details
of these unpublished data. Plasmids for lipid sensing and peptide
synthesis were co-transfected into human ﬁbrosarcoma cells, micro-
encapsulated in inert porous alginate-poly-(L-lysine)-alginate beads,
and then used in vivo studies in rats. The genetically engineered lipid
sensor is based on the nuclear lipid receptor peroxisome proliferator-
activated receptor-a (PPARa) which causes the ﬁbrosarcoma cells to
release pramlintide in a dose-dependent manner in presence of FFA
[89].
First, we conﬁrmed that pramlintide was released from co-transfected
cells in vitro and them showed that they released pramlintide into the
incubation medium upon exposure to linoleic acid (Figure 2A). We then
tested the efﬁcacy of the pramlintide-releasing microcapsules under
in vivo conditions in rats. These microencapsulated cells were injected
intraperitoneally in male SpragueeDawley rats maintained on a 60%
high fat diet (D12492, Research Diet); 20 106 cells were injected per
rats, which is 10-times more than what has been previously used in
mice [89]. High-fat diet fed rats displayed a temporary effect of fatty
acid-induced pramlintide production as compared to control animals.
Indeed, high-fat fed rats receiving pramlintide exhibited a reduction in
body weight gain although the effect waned approximately 5 days after
Figure 2: (A) Linoleic acid (LA)-induced pramlintide production in HT1080 cells at 48 h. Non-transfected cells were incubated with transfection solution without plasmids, non-
treated cells were incubated with transfection solution and 250 ng pKR135 (LSR construct) þ 250 ng pKR146 (pramlintide construct) or 250 ng pKR135 þ 500 ng pKR146, and
treated cells were transfected with 250 ng pKR135 þ 250 ng pKR146 or 250 ng pKR135 þ 500 ng pKR146 and treated daily with 100 mM linoleic acid. Values are mean  SEM,
n ¼ 4/group. Data with differing superscripts differ from each other by P ¼ 0.05 or less when assessed by two way ANOVA followed by post-hoc Bonferroni t-test. LSR-construct
alginate beads or LSR-pramlintide alginate beads were then injected i.p in male SpragueeDawley rats fed HF 60% (B) Cumulative body weight gain over the 12-day period.
*P < 0.05 after a two-way repeated measures ANOVA and post-hoc Bonferroni test. (C) Food intake in kcal after a 4 h meal test on day 3 and (D) leptin-induced anorexia at 4 h and
24 h tested in a cross-over design on day 5 and 7 post-injection. Values are mean  SEM, n ¼ 6/group, **P < 0.01 or less, using unpaired Student’s t-test.
MOLECULAR METABOLISM- (2017) 1e8  2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
5
microcapsule implantation (Figure 2B). In a fastingerefeeding test,
rats injected i.p. with the pramlintide secreting cells ate about 26%
less than control animals (Figure 2C). Further, when tested 5 and 7
days after injection, the leptin induced anorexia was ampliﬁed at 4 h by
34% in rats injected with pramlintide secreting cells. The effect of
leptin on food intake at 24 h was no longer different between groups
(Figure 2D).
When tested about 2 weeks after the implantation of the pramlintide
secreting cells, there was no enhancement of leptin signaling (leptin-
induced pSTAT3) in the hypothalamus of rats receiving pramlintide
versus control (data not shown). Possibly, this lack of effect was due to
an insufﬁcient number of cells that were still functional at this time
point. Hence, our data showed that when genetically-engineered
pramlintide-releasing cells were stimulated via the LSR plasmid
reacting to an increase in lipids in plasma, we saw effects on body
weight and eating that mimicked those observed after repeated pe-
ripheral injection of pramlintide itself. Our study extended previous
ﬁndings and demonstrated the successful but transient effect of an
autonomous genetic system providing monitoring, production and
secretion of pramlintide in rats put on a high fat diet.
6. SUMMARY
In this review, we summarized recent ﬁndings on the physiological
effects of amylin on the control of eating. We brieﬂy discussed the
potential relevance of different amylin receptor subtypes, but a
better understanding of the role of speciﬁc amylin receptor subtypes
is needed. We also summarized recent evidence that amylin, similar
to other gastrointestinal hormones, modulates both homeostatic and
hedonic feedback systems regulating ingestive behavior. Finally, we
summarized recent reports on the development of amylin analogs
that may have the potential for the development of anti-obesity
drugs.
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